A large biotech company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics globally for patients suffering from inflammatory and auto-immune diseases, has built a clinical late stage therapeutics pipeline and is seeking collaborations with companies with compelling early-stage programs and technologies within its core therapeutic areas of interest, and is willing to consider multiple partnering structures ranging from investments (active or passive) to in-licensing. While primarily interested in therapeutics, assuming a fit with the firm’s areas of interest, the firm is willing to consider partnerships and investments around other technologies. Furthermore, the firm is willing to partner with companies across the globe.
The firm’s areas of interest are in inflammation and auto-immune conditions, with a focus on GI and dermatologic disease. Also of interest are any technologies relating to the microbiome. As a secondary interest, the firm will also consider therapeutics in the cardiovascular space.
Due to their flexibility as investors, the firm can assume varying roles in a partnership depending on the level of investment. When investing alongside other firms, the firm will not necessarily require exclusive rights to the assets. For larger investments, where the firm is supporting the majority of development activities, they generally will assume an involved role as a more pro-active partner with the company.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 